SCHEDULE 13G/A: Frazier Life Sciences Funds Update Significant Stake in Trevi Therapeutics, Maintaining Passive Investment
Amended Beneficial Ownership Report
Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G/A, reaffirming their passive beneficial ownership in Trevi Therapeutics, Inc. as of December 31, 2024.
Summary
- Frazier Life Sciences Public Fund, L.P., along with its general partners FHMLSP, L.P. and FHMLSP, L.L.C., beneficially owns 8,819,620 shares of Trevi Therapeutics Common Stock, representing 9.9% of the class.
- Frazier Life Sciences X, L.P., FHMLS X, L.P., and FHMLS X, L.L.C. collectively beneficially own 428,000 shares, representing 0.5% of the class.
- Frazier Life Sciences XI, L.P., FHMLS XI, L.P., and FHMLS XI, L.L.C. collectively beneficially own 1,417,154 shares, representing 1.6% of the class.
- Key individuals James N. Topper and Patrick J. Heron each report shared beneficial ownership of 10,664,774 shares, equating to 11.9% of the class, aggregating their interests across the various Frazier Life Sciences funds.
- Albert Cha and James Brush each report shared beneficial ownership of 8,819,620 shares, or 9.9% of the class, through their association with Frazier Life Sciences Public Fund, L.P.
- Daniel Estes reports shared beneficial ownership of 1,417,154 shares, or 1.6% of the class, through his association with Frazier Life Sciences XI, L.P.
- The percentages of ownership are calculated based on 76,865,711 shares of Common Stock outstanding on October 31, 2024, and an additional 12,500,000 shares sold by Trevi Therapeutics in a public offering described in a December 16, 2024 prospectus.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by investment funds in a publicly traded biotechnology company, Trevi Therapeutics, Inc. It reflects the ongoing investment strategy of Frazier Life Sciences in the life sciences sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes held by institutional investors and their affiliates, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2016-03-29 | Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron (original filing date for Power of Attorney referenced in Joint Filing Agreement). |
| 2017-07-31 | Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron (referenced in signature section). |
| 2021-08-16 | Power of Attorney filed with the SEC for Albert Cha and James Brush. |
| 2022-04-18 | Power of Attorney filed with the SEC for Daniel Estes. |
| 2024-10-31 | Date of Common Stock outstanding count (76,865,711 shares) as per Issuer's Quarterly Report on Form 10-Q. |
| 2024-11-06 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-12-16 | Date Issuer's final prospectus pursuant to Rule 424(b)(5) was filed with the SEC, describing the public offering. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-14 | Date of filing of this Schedule 13G/A and Joint Filing Agreement. |
Keywords
Trevi Therapeutics, Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Investment Fund, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.